Xention aims to cash in ion channel knowhow through new CRO

By Staff Reporter

- Last updated on GMT

Related tags: Ion channel, Pharmacology, Drug discovery

New ion channel CRO launched in UK
New ion channel CRO launched in UK
Heart drug developer Xention has launched a contract screening business designed for drug industry customers seeking ion channel services.

The UK firm unveiled Metrion Biosciences last week, explaining that the stand alone firm will aim to cater for sponsor demand for in vitro means of testing whether drug candidates that target ion channels pose any cardiac safety risks.

According to the contractor, the plan is to launch a panel of in vitro​ cardiac ion channel and human cardiomyocyte assays for which it will seek accreditation of under the US FDA’s Comprehensive in Vitro​ Proarrhythmia Assay initiative (CIPA).

Metrion also has plans to sell a panel of neurological ion channel assays for pharmaceutical companies to profile and de-risk new drug candidates.

Keith McCullagh, chairman of parent firm Xention, stressed that the new firm would cater for growing drug industry interest in ion channel biology and will provide a way of generating revenue from Xention’s expertise in the field.

With global demand for high quality ion channel assay services growing steadily, we have identified an opportunity to commercialise Xention’s long standing specialist expertise in ion channel biology.

He added that: “Metrion Biosciences represents a new initiative to commercialise our specialist ion channel expertise on a fee-for-service basis which will be more convenient and accessible for our customers.”  

Xention’s focus is the development of drugs for the treatment of atrial fibrillation using its proprietary ion channel platform.

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related products

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Clear Guidelines for IND/CTA

Clear Guidelines for IND/CTA

Altasciences | 24-Feb-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Planning Your Preclinical Assessment

Planning Your Preclinical Assessment

Altasciences | 17-Jan-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Follow us

Products

View more

Webinars